It continues to look like a buying time exercise for now. Perhaps until AGM is sorted.Any wonder the ATO class ruling is taking a while. In the interim $568k Return of Capital is withheld.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%